Altay Biopharma
About us
The Science
Focused Therapies
About us

Altay Therapeutics Inc. discovers novel treatments for chronic inflammatory diseases and cancers.

Novel Mechanism:
Our small molecules inhibit disease-causing transcription factors by disrupting their association with DNA.

Robust Platform and screening approach:
Our platform identifies novel transcription factors as targets for a wide range of diseases and develops novel DNA binding inhibitors.

Preclinical findings:
Our small molecules have shown exceptional results in several animal models for fibrotic diseases such as lung and liver fibrosis as well as several cancers. 
The Science

Altay develops novel small molecules that inhibit transcription factors that are validated drivers of disease. Our platform, enables us to identify new targets in a variety of therapeutic areas and generate inhibitors using our screening approach. Our mechanism of inhibition enables us to drug the "undruggable", giving us a leading advantage over our competitors.

Our first cellular target is a key driver of inflammation and cell transformation during disease initiation and progression.

Focused Therapies

Altay focuses on finding safe and potent treatments for chronic inflammatory diseases such as fibrosis, rheumatoid arthritis, ulcerative colitis, and several cancers.


Clinic by Q3 2022. We are focused on finding treatments for chronic inflammatory liver diseases such as NASH and liver cancer. We expect to nominate a lead drug for liver diseases by Q1 of 2021. 

Our pre-clinical studies for prostate cancer and Ewings Sarcoma show great efficacy. We expect to nominate a lead for our prostate cancer program by Q2 of 2021. 


Ali Rayet Ozes. PhD.

Founder and CEO

  * Lead scientist. Mechanism of small molecules for oncology program - Nalo Therapeutics

  * Post-doctoral Researcher - Janssen Biopharma

  * University of California, Davis (B.S.) - Indiana University (PhD.)

Osman Nidai Ozes. PhD.

Founder and CSO

  * Professor of Genetics. Mechanism of inflammatory response in cancer - Akdeniz University

  * Director of Research. Lead of idiopathic lung fibrosis (IPF) program- Intermune Inc.

  * Haccettepe University (B.S and M.S.) - Indiana University (PhD) - Indiana University (Postdoc)

Lee Latimer. PhD.

Medicinal Chemistry

* Board of Directors, director-at-large - American Chemical Society (2016-2018)

* Senior Director, Process and Analytical Chemistry - Elan Inc. (1995-2011)

* Tulane University (B.S.) - University of Wisconsin (PhD.) - University of California Berkeley (Postdoc)

 Marc Evanchik. PhD.


* Senior Director, DMPK - Assembly Biosciences

* Senior Director, Pharmacology - MyoKardia

* University of California, Santa Cruz (B.S.) - University of California, Davis (M.S.)

Kamran Atabai. MD.

Fibrosis Consultant

* Associate Professor of Medicine - University of California San Francisco

* Fellowship / Pulmonary and Critical care - Harvard

* Residency / School of Medicine - University of California San Francisco

Altay is located at the Bayer Colaborator in San Francisco Mission Bay.

For more information please contact us:


455 Mission Bay

Boulevard South

San Francisco, CA 94158